Drug intelligence / Profile preview

APN-346958

Development stage: Unknown
Lead developer: Atreca
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

**APN-346958** is a preclinical CD3-engager antibody discovered by Atreca using its immune response-based discovery platform. It recognizes a novel tumor-selective RNA-binding protein target, exhibiting immunoreactivity in at least 50% of samples across six tumor types and demonstrating compelling anti-tumor activity in preclinical in vivo studies. Initially developed as part of Atreca's oncology pipeline expansion, it leverages T cell engagement via CD3 stimulation for potential immuno-oncology applications.[1][2][3][5]

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on APN-346958.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APN-346958.

Explore the full profile